Transplantation Solid Tumor Registry, Lyon; Institute Gustave

Purpose: Relapse from stage 4 neuroblastoma usu-ally carries a poor prognosis. A retrospective study using the European Bone Marrow Transplant (EBMT) Solid Tu-mor Registry was undertaken to define the role of megatherapy (MGT) in relapsed patients. Patients and Methods: After relapse, 33 boys and 15 girls with previous stage 4 neuroblastoma received in-tensification by MGT followed by either autologous (n = 42) or allogeneic (n = 6) bone marrow rescue in 11 European institutions. The median age at diagnosis was 47 months (range, 14 to 134) and the median interval from diagnosis to relapse was 16 months (range, 4 to 94). Thirty patients had received only conventional-dose primary treatments (group A), whereas 18 patients had previously received intensification with MGT (group B)